All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bupivacaine,Meloxicam
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
HTX-011 reduced pain and opioid use after primary total knee arthroplasty, The study met all primary and key secondary endpoints, with HTX-011 demonstrating statistically significant reductions in pain intensity following surgery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Calcium Phosphate,Blood-derived component
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Calcium Phosphate
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
Details:
Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.